| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701761 | Journal of Thoracic Oncology | 2016 | 23 Pages |
Abstract
The use of PORT in patients with advanced thymic malignancies is increasing over time and is determined by both clinical and demographic factors. Receipt of PORT was associated with improved OS. The OS benefit with PORT was dependent on the WHO histologic type.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Dustin MD, Andrew MD, Cameron BS, Kristine MD, Ying J. MD,